Salarius Pharmaceuticals, Inc.

DCOY Nasdaq CIK: 0001615219

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
Mailing Address 2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
Phone 346-772-0346
Fiscal Year End 1231
EIN 465087339

Financial Overview

FY2024

-$5.58M
Net Income
$6.59M
Total Assets
$1.51M
Total Liabilities
$10.38M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement January 9, 2026 View on SEC
8-K Current report of material events January 8, 2026 View on SEC
8-K Current report of material events January 2, 2026 View on SEC
8-K Current report of material events January 2, 2026 View on SEC
4 Insider stock transaction report January 2, 2026 View on SEC
8-K Current report of material events December 19, 2025 View on SEC
3 Initial insider ownership report November 24, 2025 View on SEC
3 Initial insider ownership report November 24, 2025 View on SEC
3 Initial insider ownership report November 24, 2025 View on SEC
4 Insider stock transaction report November 24, 2025 View on SEC

Material Events

8-K Financial Distress January 2, 2026
High Impact
  • Salarius Pharmaceuticals received a notice from Nasdaq regarding delisting due to its common stock's closing bid price falling below $1.00 for 30 consecutive business days.
  • The company is not eligible for the usual grace period due to a recent reverse stock split and being under a 'Mandatory Panel Monitor' by Nasdaq.
View Analysis

Insider Trading

BUY 2 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.